Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized hPMSC-EVs in Idiopathic Pulmonary Fibrosis
NCT07515066Phase 1Not yet recruiting
- Sponsor
- Huanye Pharmaceutical
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 3D-cultured human placental mesenchymal stem cell-derived extracellular vesicles in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Huanye Pharmaceutical. Primary endpoints: Incidence and severity of adverse events and serious adverse events at Day 35 and Maximum tolerated dose at Day 28. Planned start May 2026; status: not yet recruiting.
02
Drugs
3D-cultured human placental mesenchymal stem cell-derived extracellular vesicles
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07515066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515066.